Literature DB >> 31209649

Interpreting desirability of outcome ranking (DOOR) analyses in observational studies in infectious diseases: caution still needed.

Daniele Roberto Giacobbe1,2, Alessio Signori3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31209649     DOI： 10.1007/s10096-019-03612-0

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  5 in total

1.  Desirability of outcome ranking (DOOR) for comparing diagnostic tools and early therapeutic choices in patients with suspected candidemia.

Authors:  Daniele Roberto Giacobbe; Alessio Signori; Mario Tumbarello; Riccardo Ungaro; Giovanni Sarteschi; Elisa Furfaro; Malgorzata Mikulska; Maurizio Sanguinetti; Brunella Posteraro; Angela Raffaella Losito; Gennaro De Pascale; Valerio Del Bono; Claudio Viscoli
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-11-30       Impact factor: 3.267

2.  Impact of macrolide therapy in critically ill patients with acute respiratory failure: a desirability of outcome ranking analysis to investigate the OUTCOMEREA database.

Authors:  Stéphanie Pons; Jean-François Timsit; Stéphane Ruckly; Carole Schwebel; Laurent Papazian; Elie Azoulay; Jean Reignier; Lara Zafrani
Journal:  Intensive Care Med       Date:  2019-03-14       Impact factor: 17.440

3.  Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Authors:  Sarah B Doernberg; Thuy Tien Tram Tran; Steven Y C Tong; Mical Paul; Dafna Yahav; Joshua S Davis; Leonard Leibovici; Helen W Boucher; G Ralph Corey; Sara E Cosgrove; Henry F Chambers; Vance G Fowler; Scott R Evans; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

4.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

5.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.